Immuron (IMRN) Current Leases (2018 - 2026)

Immuron (IMRN) posted Current Leases of $158937.0 for Q3 2026, up 121.19% on a QoQ basis from $71855.0 in Q4 2025.

Analysis

Immuron (IMRN) Current Leases (2018 - 2026) Analysis & Trends

Immuron has reported Current Leases for 4 years, with the latest figure at $158937.0 in Q3 2026.

On a quarterly basis, Current Leases changed N/A year-over-year to $158937.0 in Q3 2026; TTM through Aug 2026 was $158937.0, a N/A change from a year earlier, with the FY2026 full-year figure at $158937.0, changed N/A from the prior year.
Current Leases was $158937.0 for Q3 2026 at Immuron, up from $71855.0 in the prior quarter.
The five-year high for Current Leases was $158937.0 in Q3 2026, with the low at $71855.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	-
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	720.00 Mn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	11.00 Mn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	45.93 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	-
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	12.38 Mn
10	Immuron	10.28 Mn	1.26 Mn	-	158,937.00

Historic Data

Download Data